Pulmonary Fibrosis
Latest News
Insights Into Pulmonary Fibrosis Pathogenesis, Treatments, and the Potential Role of Traditional Chinese Medicine
AIM-30 Score Predicts Mortality Following Acute Exacerbation of IPF
Metabolites With Potential Role in IPF Identified by Genome-Wide Association Study
Advancing IPF Care: New Evidence and Economic Considerations in Treatment Decision-Making
Learn about the clinical and economic burden of idiopathic and progressive pulmonary fibrosis; the need for earlier diagnosis and improved care coordination; and emerging therapies that may close treatment gaps.
Impact of Treatment Delays on Patient Outcomes
Overcoming Treatment Barriers: Strategies for Success
Clinical Presentation and Risk Factors
Impact of Comorbidities on IPF Management
Diagnosing IPF: Key Tests, Time to Diagnosis, and Importance of Early Detection
Impact of IPF on Quality of Life and Financial Considerations
Overview of Idiopathic Pulmonary Fibrosis (IPF)
Unmet Needs in IPF Landscape
Economic Impact of IPF
Key Considerations for Selecting IPF Treatment
Lack of Diversity in Pulmonary Fibrosis Genetic Studies Limits Clinical Applicability: Ayodeji Adegunsoye, MD, PhD, MSc
IPF Progression Insights From Telomere Mutations, MUC5B Polymorphism: Ayodeji Adegunsoye, MD, PhD, MSc
Early Diagnosis and Emerging Therapies in IPF Offer Hope: Marilyn Glassberg, MD
COVID-19’s Hidden Toll: Noah Greenspan, DPT, on Inflammation, Flares, and Recovery
Uncovering the Gaps: Study Sheds Light on Racial Disparities in IPF Outcomes
Dr Cesar Davila-Chapa Calls for Awareness of Racial Differences in IPF Hospitalization
Role of Immunosuppressive Therapies in Managing ILD
The Impact of FVC Decline and Lung Function in IPF
Promising Clinical Trial Updates in IPF/PPF
Dr Martin Kolb Discusses Combination Therapies and the Future of IPF Treatment
More News
Key ILD Topics at Mount Sinai’s Advances in Pulmonary Medicine 2024
